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Potentially, the induction of myeloid leukaemia cells to
differentiate into phenotypes possessing the characteristics of
normal leucocytes with an abolished or reduced capacity to
proliferate provides an alternative to conventional methods
of treatment for this disease. A variety of agents have been
shown to induce in vitro maturation of human acute myeloid
leukaemia cells (Koeffler, 1983; Gabrilove, 1986) but none
have been proven to possess therapeutic value.
Differentiation inducing factor (DIF) is a lymphokine closely
related to the colony stimulating factors (CSFs), which is
released by mitogen stimulated human leucocytes, and which
shares extensive amino acid homology with tumour necrosis
factor (TNF) (Takeda et al., 1986). Both DIF (Olsson et al.,
1984) and recombinant human TNF (rhTNF) (Trinchieri et
al., 1986) stimulate in vitro maturation of HL60 cells, a
human myeloblastic cell line (Collins et al., 1977). It is of
interest to determine whether the differentiation inducing
properties of TNF are retained in vivo. In this study we have
compared the effects of rhTNF (PAC 4D; Asahi, Tokyo) on
HL60 cells grown either in culture or as xenografts in
immune-deprived mice. The effect of rhTNF on xenografts
established directly from a population of primary human
acute myeloid leukaemia (AML) cells is also described.
HL60 cells were grown in RPMI 1640 growth medium
supplemented with 15% fetal calf serum (FCS). For routine
passage and for experimental purposes cells were taken from
logarithmic phase cultures and reseeded at a concentration
of 2 x 104 ml-1. Viability was assessed using trypan blue dye
exclusion. Cytoplasmic superoxide anion production was
detected by the reduction of nitroblue tetrazolium (NBT) dye
to form a blue-black formazan precipitate. Superoxide anion
production can be stimulated in mature myeloid cells but not
in immature forms which include the myeloblastic HL60
cells. The reduction of NBT can thus be used as a marker
for cell maturation. Cells were incubated at 37°C for 20min
in the presence of 0.5mgml-1 NBT (Sigma) and 0.05ggml-1
phorbol myristate acetate (Sigma) before scoring using a
haemocytometer.
Xenografts were established in thymectomised and total
body irradiated mice (Clutterbuck et al., 1985) by
subcutaneous implant into the flank of 1-2 x 106 HL60 cells,
or 2 x 107 primary peripheral blood AML cells (EK.AML)
taken from stock frozen in liquid nitrogen. Mice were treated
with seven daily intraperitoneal injections of 2 x107 units
kg-' rhTNF. Control mice were given carrier alone (PBS
with 0.1% gelatin). Tumours were measured using calipers
and volumes calculated as previously described.
The dose response of HL60 cells to a 6-day incubation
with rhTNF in terms of induction of maturation and
inhibition of proliferation is shown in Figure 1. Maximum
stimulation of superoxide was observed at rhTNF concen-
trations of 100Uml-1 and above, resulting in 60% of cells
acquiring the ability to reduce NBT. This represents a 3-4-
fold increase over the maximum NBT reduction activities in
rhTNF induced HL60 cells reported by Trinchieri et al.
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Figure 1 Effect of increasing concentrations of rhTNF on HL60
cell nitroblue tetrazolium reducing ability (a) and viable cell
numbers (b) after 6 days incubation in suspension culture. Points
represent the means of evaluations from three experiments. Error
bars indicate the standard error of the mean.
(1986). Dual esterase staining showed these cells to possess
cytoplasmic non-specific esterase (NSE) but not chloro-
acetate esterase, and thus to be of monocyte/macrophage
phenotype. At a concentration of 1 Uml- rhTNF 16% of
cells contained detectable NSE compared with <1% in
control cultures. Concomitant with the acquisition of NBT
reducing ability was a decrease in cell number, with maxi-
mum inhibition of proliferation observed at 100Uml-1
rhTNF. During the 6-day incubation period cell viability
remained at >90% in all cultures. We investigated the effect
of preincubation with rhTNF on the clonogenicity of HL60
cells in semi-solid culture and their ability to form tumours
in immune-deprived mice. Cells were grown for 4 days in the
presence or absence of 2 x 103 Uml1 rhTNF. The results of
these experiments are shown in Table I. In two experiments
rhTNF incubation reduced plating efficiency to 20% and
25% of the control values as estimated by the scoring of day
14 colonies. This was reflected in a reduction in the ability of
subcutaneous implants of 2 x 106 washed viable cells to form
tumours. In the first experiment 100% of cell inoculi from
control cultures had produced palpable tumours 12 days
after implant, whereas no tumours had arisen from the
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Table I Effect of preincubation with rhTNF on the clonogenicity and tumorigenicity of HL60 cells
Colonies Tumour take-rates Tumour volume (mm3)
Viability NBT+ve (per 500
(%) (%) cells) Day 12 Day 18 Day 18 Day 28
Exp. I
Control 98 <0.5 73.2+6.2 10/10 10/10 139+ 19 737+77
rhTNF 92 43 14.4+3.3 0/10 10/10 75+8 446+114
(P<0.025) (P<0.005)
Exp. 2
Control 89 <0.5 67.3+2.3 5/8 7/8 248+30 530+119
rhTNF 91 19 17.0+2.5 2/8 6/8 94+14 115+23
(P<0.005) (P<0.005)
Errors are standard errors of the mean. P values were calculated using Student's t test.
implants of cells incubated with rhTNF (five mice with 10
implants per group). However, tumour formation was not
completely inhibited by incubation with rhTNF, and by day
18 post-implant 100% of these inoculi had also produced
tumours. The mean volume of these tumours remained at
approximately 50% of that for control tumours until the
experiment was stopped (day 34). In the second experiment
tumour take-rate was again similar (control, 7/8; rhTNF,
6/8: four mice per group), with the appearance of palpable
tumours being delayed by approximately 4 days by pre-
incubation with rhTNF. Twenty-eight days after implant
tumours established from rhTNF cultures had attained a
mean volume of only 22% of that for control tumours.
Repeated daily administration of 2 x 106 Ukg-1 rhTNF in
two experiments produced no observable modification of the
growth of HL60 tumours pre-established in immune-
deprived mice (data not shown). At the termination of the
first experiment, 3 days after cessation of rhTNF dosing,
both control and treated tumour volumes had increased
approximately 8-fold above that of their pretreatment
volumes. The second experiment showed tumours to be
similarly unresponsive to rhTNF and was terminated 24h
after the final injection of rhTNF. Tumours from both
control and treated groups were excised at this time and
examined histologically. Cells remained predominantly blast-
like with only the occasional cell possessing a banded or
lobed nucleus (<1 %), with no difference being observed
under light microscopy between control and treated groups.
Cytochemical staining of frozen sections revealed no
difference between control and treated tumours in numbers
of cells staining positive for NSE. Cell suspensions made by
the mechanical disaggregation of pooled tumour tissue from
four control or four treated mice contained similar
proportions of viable cells; 42% and 43%, respectively, as
assessed by trypan blue exclusion. These cell suspensions also
contained similar proportions of cells with NBT reducing
activity; 6% and 8%, respectively. Femoral CFU-S contents
in these mice were assayed according to the method of Till &
McCulloch (1961). The mean CFU-S content per femur in
four mice treated with rhTNF was 275 (standard error 48),
compared with 1,375±210 in four control animals (P<0.01).
Despite this reduction in haemopoietic stem cell numbers a
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Figure 2 Effect of repeated daily i.p. injections (arrows) of
rhTNF (open symbols) or diluent (see text) alone (filled symbols)
on the growth of primary human EK.AML cells (from frozen
stock) as subcutaneous tumours in immune-deprived mice. Points
represent mean tumour volumes (V,) as a ratio of pretreatment
volumes (VO). Error bars indicate the standard error of the
mean. Five to six mice (9-11 tumours) per group.
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Figure 3 Effect of increasing concentrations of rhGM-CSF on
HL60 cells grown in suspension culture for 6 days. Initial cell
concentration was 2 x 104ml-'. (a) Day 6 cell concentrations in
cultures containing rhGM-CSF only, expressed as a ratio of the
cell number in control (no rhGM-CSF) cultures. Columns
represent the mean ratios of six experiments. (b) Day 6 cell
concentrations in cultures containing rhGM-CSF and 100 units
ml-' rhTNF, expressed as a ratio of the cell number in cultures
containing 100 units ml-' rhTNF only. Columns represent the
mean ratios of five experiments. (c) Numbers of cells possessing
nitroblue tetrazolium (NBT) reducing ability in cultures
containing rhGM-CSF and 100 units ml-' rhTNF. Percentages
of NBT reducing cells in rhGM-CSF cultures are expressed as a
ratio of the percentage of NBT reducing cells in cultures
containing 100 units ml-' rhTNF only. Columns represent the
mean ratios of five experiments. Error bars indicate the standard
errors of the mean ratios. Differences between control cultures
and cultures containing rhGM-CSF were tested non-
parametrically for significance using analysis of variance
(Dunnett's procedure). Significant differences are indicated by
one (P<0.05) or two (P<0.01) asterisks.
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rapid increase in peripheral blood leucocyte count was
observed in rhTNF treated mice, as has been reported in
patients treated with this cytokine (Selby et al., 1987).
Transient reductions in body weight (approximately 5%
below that of control mice) were also observed in rhTNF
treated animals.
Although the effects on normal tissues indicate that
rhTNF at the dose used was active in vivo, it is possible that
HL60 tumours received insufficient levels of cytokine to
induce maturation or inhibit proliferation. However, in
tumour bearing mice treated with 1 x 106 Ukg 1 rhTNF
(50% of the dose used in our experiments), plasma levels of
rhTNF remained above 10OUml-m for 5h following i.p.
injection (T. Shiga, personal communication). We also
investigated the response to rhTNF of xenografts established
from a population of primary AML cells (EK.AML). These
tumours were responsive to the treatment regimen of 7 daily
injections of 2 x 106Ukg-1 rhTNF (Figure 2). The slope of
the growth curve of rhTNF treated tumours was significantly
less than that of control tumours (Student's t test, P<0.01).
Individual cell suspensions made 24h after the last treatment
in a repeat experiment contained mean viabilities of 55%
(n=4) in the untreated group and 8% (n=5) in the treated
group. Such low fractions of viable cells from tumours
treated with rhTNF precluded cytochemical analysis. The
effects on body weight and leucocyte count were similar to
those described for HL60 tumour bearing mice. EK.AML
cells failed to proliferate in continuous suspension culture,
and so a direct comparison of the responses in vitro between
these cells and HL60 cells was not possible.
The effect of recombinant human granulocyte/macrophage
colony stimulating factor (rhGM-CSF) on rhTNF induced
HL60 cell differentiation in vitro was investigated. rhGM-
CSF (Sandoz) alone stimulated proliferation of HL60 cells
(Figure 3). This effect was dose-dependent. No increase was
seen in the number of cells with NBT reducing activity (data
not shown), despite previous reports that HL60 cell differen-
tiation was induced by GM-CSF (Tomonoga et al., 1986;
Begley et al., 1987). The inhibition of growth produced by
rhTNF was partially reversed by rhGM-CSF (Figure 3b)
with a concomitant decrease in proportions of cells with
NBT reducing activity (Figure 3c). This observation is
probably comparable with the modulation of the inhibitory
action of rhTNF on human CFU-GM growth stimulated by
CSF from different sources (Munker & Koeffler, 1987).
EGF, TGF-x and TGF-f have also been shown to interfere
with the in vitro antiproliferative effects of rhTNF
(Sugarman et al., 1987).
These results demonstrate an anti-leukaemic effect of
rhTNF against human EK.AML xenografts, but at a dose
which produces plasma levels that are higher than those
safely attainable in man (Selby et al., 1987). rhTNF activity
against HL60 cells in vitro was not reproduced in vivo,
possibly due in part to the presence of other growth factors.
Cells from many AML patients produce their own CSFs
(Young et al., 1988) and may thus be rendered less suscep-
tible to the antiproliferative/differentiative effects of rhTNF.
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